cover image Explore emerging cell and gene therapies, rare disease innovation and payer strategies shaping the specialty pipeline. Prime Therapeutics /spring-2026-prime-therapeutics-report The...

Cover image for Drug Approvals Monthly Update: September 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Cover image for Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....

Hear some of the latest insights from the annual managed care pharmacy event, where Prime Therapeutics clinical and health outcomes teams presented leading research findings

In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)'s 2024 Annual Meeting in New Orleans

Formulary design recommendations help create competition to drive savings, provide optionality to meet unique client needs.

Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...

Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

A gene therapy product approved for adults with hemophilia B may increase initial costs for health plans but can reduce expenditures by nearly $1 million over time, according to a recent study

In this special episode of the Pharmacy Friends podcast, “Live at Specialty Summit ’24 – Connect. Elevate. Transform.,” we are on the road in New York City at our 21st annual Specialty Summit. More...

Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Home News & Insights Research & publications Archived Content High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel...

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years...

Experts outline clinically grounded strategies to manage cost, improve outcomes and coordinate care across benefits

If you think about the rise of specialty drugs as a Category 5 hurricane, and the growth of gene therapies as an undersea earthquake, you can see the rising tsunami of drug spend looking to sweep...

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

The SIU promotes safety to prevent fraud, waste and abuse schemes

Dinesh Kandanchatha joined the organization July 1.

cover image This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime Therapeutics...

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Recent webinar featuring Prime Therapeutics experts shares some of the latest breakthrough therapies — including ADCs, BiTes and CAR-T treatments — and regulatory changes and market shifts that are...

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Prime Therapeutics offers first-of-its-kind digital utilization management solution that pairs biomarker testing with targeted therapy drug selection

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...

This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point

Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars

Prime Therapeutics offers innovative medication management solutions, supports patients with chronic conditions

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...

Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...

In recent years, there have been significant advances in drug development to identify and target disease-causing genetic mutations.1 In order to achieve disease response, drugs commonly bind to a...

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

Lead author David Eckwright shares more about the study “Real-World Extended Dosing Assessment for Eye(s) new to Faricimab-svoa Therapy.”

Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...

New report highlights value-based contract solution and analysis of top 10 drug classes impacting Medicaid pharmacy net trend

As the efficacy and cost of these therapies become clear, so is the need for thoughtful managed care strategies, according to Prime Therapeutics thought leaders

Studies aim to highlight the impact of various healthcare strategies and programs on patient outcomes and cost containmenta

References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....